221 related articles for article (PubMed ID: 25122543)
1. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
2. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.
Díaz-Montero CM; Zidan AA; Pallin MF; Anagnostopoulos V; Salem ML; Wieder E; Komanduri K; Montero AJ; Lichtenheld MG
Immunol Res; 2013 Dec; 57(1-3):23-33. PubMed ID: 24218360
[TBL] [Abstract][Full Text] [Related]
3. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
4. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous assessment of antigen-stimulated cytokine production and memory subset composition of memory CD8 T cells.
Jabbari A; Harty JT
J Immunol Methods; 2006 Jun; 313(1-2):161-8. PubMed ID: 16762359
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
7. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
9. Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
Schuster K; Gadiot J; Andreesen R; Mackensen A; Gajewski TF; Blank C
Eur J Immunol; 2009 Nov; 39(11):2981-90. PubMed ID: 19658092
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes.
Jackson SS; Schmitz JE; Kuroda MJ; McKay PF; Sumida SM; Martin KL; Yu F; Lifton MA; Gorgone DA; Letvin NL
Immunology; 2005 Dec; 116(4):443-53. PubMed ID: 16313358
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
12. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
13. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L.
Bachmann MF; Wolint P; Schwarz K; Jäger P; Oxenius A
J Immunol; 2005 Oct; 175(7):4686-96. PubMed ID: 16177116
[TBL] [Abstract][Full Text] [Related]
14. L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy.
Watson HA; Durairaj RRP; Ohme J; Alatsatianos M; Almutairi H; Mohammed RN; Vigar M; Reed SG; Paisey SJ; Marshall C; Gallimore A; Ager A
Front Immunol; 2019; 10():1321. PubMed ID: 31249570
[TBL] [Abstract][Full Text] [Related]
15. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.
Sluijter BJ; van den Hout MF; Stam AG; Lougheed SM; Suhoski MM; van den Eertwegh AJ; van den Tol MP; van Leeuwen PA; Meijer S; Scheper RJ; June CH; de Gruijl TD; Santegoets SJ
Clin Immunol; 2010 Nov; 137(2):221-33. PubMed ID: 20708974
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
Umansky V; Abschuetz O; Osen W; Ramacher M; Zhao F; Kato M; Schadendorf D
Cancer Res; 2008 Nov; 68(22):9451-8. PubMed ID: 19010920
[TBL] [Abstract][Full Text] [Related]
18. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes.
Yang S; Liu F; Wang QJ; Rosenberg SA; Morgan RA
PLoS One; 2011; 6(7):e22560. PubMed ID: 21829468
[TBL] [Abstract][Full Text] [Related]
19. AsialoGM1+CD8+ central memory-type T cells in unimmunized mice as novel immunomodulator of IFN-gamma-dependent type 1 immunity.
Kosaka A; Wakita D; Matsubara N; Togashi Y; Nishimura S; Kitamura H; Nishimura T
Int Immunol; 2007 Mar; 19(3):249-56. PubMed ID: 17229818
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
